Brought to you by:
VIVA 2021: IVL ‘consistently’ treats real-world calcium in multiple peripheral vessel beds
An interim analysis from the DISRUPT PAD III observational study showed that intravascular lithotripsy (IVL) performs “consistently well” across challenging peripheral vessels, lesions and subgroups of patients, Ehrin J. Armstrong, MD, medical director at Adventist Heart and Vascular Institute in…
Two-year Ranger DCB data demonstrate ‘sustained, high rate’ of device efficacy
Patients treated with Boston Scientific’s Ranger drug-coated balloon (DCB) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year results from the RANGER II SFA randomized controlled trial have demonstrated, investigators revealed during a late-breaking session…
VIVA 2021: IN.PACT Admiral DCB found to provide ‘high five-year freedom from clinically driven TLR’ in patients with complex lesions
Real-world data drawn from the IN.PACT Global study looking at five-year freedom from clinically driven target lesion revascularization (TLR) among prespecified chronic total occlusion (CTO), long lesion and de novo in-stent restenosis (ISR) cohorts “continues to confirm long-term clinical safety…
Intravascular lithotripsy ‘superior’ to PTA in acute procedural success out to 30 days
The DISRUPT PAD III randomized controlled trial (RCT) provides the largest level-one evidence for the treatment of heavily calcified femoropopliteal arteries, noted William Gray, MD, an interventional cardiologist at Main Line Health, Philadelphia, during the second and final late-breaking data…
Latest VOYAGER PAD analysis finds no mortality and improved limb outcomes in drug-coated device cohort
Given the absence of a safety signal in data from the VOYAGER PAD trial, a new analysis examined the potential benefit of drug-coated device versus non-drug-coated device treatment for reducing limb outcomes. Connie Hess, MD, an associate professor of cardiology…
Medical education requires a reboot in the digital age, argues stent-grafting pioneer
LAS VEGAS—Medical education is confronted by huge opportunities with the coming of what has been termed the fourth industrial revolution—that of the intersection where “big biology and big medicine” meet “big data.” Those were the sentiments of Michael Dake, MD,…